Suppliers and packagers for generic pharmaceutical drug: HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Mylan Speciality Lp	EPIFOAM	hydrocortisone acetate; pramoxine hydrochloride	AEROSOL, METERED;TOPICAL	086457	ANDA	Viatris Specialty LLC	0037-6824-10	1 CANISTER in 1 CARTON (0037-6824-10) / 10 g in 1 CANISTER	2014-08-25
Mylan Speciality Lp	PROCTOFOAM HC	hydrocortisone acetate; pramoxine hydrochloride	AEROSOL, METERED;TOPICAL	086195	ANDA	Viatris Specialty LLC	0037-6822-10	1 CANISTER in 1 CARTON (0037-6822-10) / 10 g in 1 CANISTER	2014-08-15
Legacy Pharma	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	CREAM;TOPICAL	085368	ANDA	Padagis Israel Pharmaceuticals Ltd	45802-144-64	1 TUBE in 1 CARTON (45802-144-64) / 28.35 g in 1 TUBE	2010-04-13
Legacy Pharma	PRAMOSONE	hydrocortisone acetate; pramoxine hydrochloride	CREAM;TOPICAL	085368	ANDA	Sebela Pharmaceuticals Inc.	54766-716-03	57 g in 1 TUBE (54766-716-03)	2015-08-04

Global Supply Chain Analysis: Hydrocortisone Acetate and Pramoxine Hydrochloride

Last updated: February 19, 2026

Executive Summary

This report analyzes the global supply landscape for Hydrocortisone Acetate (HCA) and Pramoxine Hydrochloride (PHC), active pharmaceutical ingredients (APIs) critical for topical dermatological treatments. Key manufacturers are identified across major manufacturing regions, including India, China, and the United States. The analysis focuses on production capacity, regulatory compliance, and potential supply chain vulnerabilities. Demand for these APIs is driven by the persistent prevalence of inflammatory skin conditions and the consistent market for over-the-counter (OTC) and prescription topical corticosteroids and local anesthetics.

Hydrocortisone Acetate (HCA) Supply Landscape

What are the primary global manufacturers of Hydrocortisone Acetate?

The global production of Hydrocortisone Acetate is concentrated among a limited number of API manufacturers, with significant capacity located in India and China. These regions offer cost advantages in manufacturing and established chemical synthesis infrastructure.

• Major Manufacturers:
  • India: Several Indian pharmaceutical companies are significant producers of HCA. These companies often have integrated manufacturing capabilities and strong export networks. Examples include:
    • Divi's Laboratories Limited
    • Laurus Labs Limited
    • Aarti Industries Limited
  • China: Chinese API manufacturers also play a substantial role in the global HCA supply. Their production is often characterized by large-scale output and competitive pricing. Examples include:
    • Zhejiang NHU Co., Ltd.
    • Zhejiang Medicine Co., Ltd.
  • United States: While less dominant in terms of sheer volume compared to India and China, some US-based manufacturers maintain HCA production, often focusing on specialized grades or serving domestic demand with stringent quality control.

What are the typical production capacities and quality standards for HCA?

Production capacities for HCA vary significantly between manufacturers, ranging from tens to hundreds of metric tons annually. The quality standards for HCA are dictated by pharmacopoeial requirements, primarily the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP). Manufacturers must adhere to these standards, as well as Good Manufacturing Practices (GMP) mandated by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

• Capacity Range: Manufacturers typically report capacities in the range of 20-150 metric tons per year for HCA. This can fluctuate based on market demand and individual company investment in expansion.
• Quality Adherence:
  • USP/EP Compliance: HCA must meet specified limits for purity, impurities, residual solvents, and physical characteristics (e.g., particle size distribution) as outlined in the respective pharmacopoeias.
  • GMP Certification: Facilities producing HCA are subject to regular inspections by regulatory authorities. Certifications such as FDA GMP, WHO GMP, and EDQM (European Directorate for the Quality of Medicines & HealthCare) CEP (Certificate of Suitability to the monographs of the European Pharmacopoeia) are critical for market access in regulated territories.

What are the key regulatory considerations for HCA sourcing?

Sourcing HCA requires thorough due diligence regarding regulatory compliance and supply chain integrity. Manufacturers must possess the necessary regulatory filings and certifications to supply to target markets.

• Drug Master Files (DMFs): API manufacturers typically file DMFs with regulatory agencies like the FDA. A US-DMF provides confidential detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. This allows drug product manufacturers to reference the DMF in their own drug applications.
• CEP Certificates: For the European market, a CEP issued by the EDQM demonstrates that the API complies with the relevant monograph of the European Pharmacopoeia.
• Import/Export Regulations: Navigating international trade regulations, tariffs, and customs procedures is essential. Manufacturers must ensure their products comply with the importing country's chemical and pharmaceutical regulations.

Pramoxine Hydrochloride (PHC) Supply Landscape

Who are the leading global suppliers of Pramoxine Hydrochloride?

Pramoxine Hydrochloride, a topical anesthetic, is manufactured by a select group of API producers, with a strong presence in Asia. The supply chain for PHC is less dispersed than for HCA, but a similar cost-competitiveness dynamic exists.

• Key Suppliers:
  • China: Chinese manufacturers are prominent in the PHC supply chain, offering competitive pricing and significant volume.
  • India: Indian pharmaceutical companies also contribute to the global PHC supply, often with a focus on meeting stringent quality requirements for Western markets.
  • Other Regions: Limited production may exist in other regions, but is generally less significant in terms of global market share.

What are the typical manufacturing processes and purity requirements for PHC?

The synthesis of Pramoxine Hydrochloride involves multi-step organic chemistry processes. Purity and the absence of specific related substances are paramount due to its use in topical formulations that come into contact with skin.

• Synthesis: Common synthetic routes involve etherification and amination steps to form the pramoxine base, followed by salt formation with hydrochloric acid.
• Purity Standards: PHC must meet pharmacopoeial specifications, typically USP and EP, for assay (purity), related substances (impurities), heavy metals, and loss on drying.
  • Assay: Typically 98.0% to 102.0% on the dried basis.
  • Related Substances: Specific limits are set for known and unknown impurities, often requiring sophisticated analytical techniques like High-Performance Liquid Chromatography (HPLC) for detection and quantification.

What are the critical factors in PHC supply chain reliability?

Reliability in PHC supply hinges on consistent manufacturing quality, adherence to regulatory standards, and robust supply chain management by the API producer.

• Quality Management Systems: Manufacturers must have well-established Quality Management Systems (QMS) in place, including robust change control, deviation management, and CAPA (Corrective and Preventive Actions) processes.
• Batch-to-Batch Consistency: Demonstrating consistent quality across different production batches is crucial for pharmaceutical product manufacturers. This is achieved through rigorous in-process controls and final product testing.
• Supplier Audits: Pharmaceutical companies routinely audit their PHC suppliers to verify GMP compliance, assess risk, and ensure the security of the supply chain. These audits often cover manufacturing processes, quality control laboratories, and warehousing.

Comparative Analysis: HCA vs. PHC Supply Chains

How do the supply chains for HCA and PHC compare in terms of complexity and risk?

While both HCA and PHC are widely used dermatological APIs, their supply chains exhibit distinct characteristics in terms of manufacturer concentration, production volume, and regulatory scrutiny.

• Manufacturer Concentration:
  • HCA: A larger number of manufacturers, particularly in India and China, compete in the HCA market. This can lead to more competitive pricing but also a more fragmented supplier base.
  • PHC: The supplier base for PHC appears to be more concentrated, with a smaller number of key players. This can increase reliance on fewer suppliers.
• Production Volume: HCA is a more widely produced steroid with broader applications, potentially leading to higher overall global production volumes compared to PHC, which is more specific in its topical anesthetic use.
• Regulatory Scrutiny: Both APIs are subject to rigorous regulatory oversight. However, the classification of HCA as a corticosteroid may attract slightly different regulatory attention regarding efficacy, safety, and potential for misuse or diversion, although both are controlled substances in pharmaceutical products.
• Supply Chain Risk Factors:
  • Geopolitical Stability: Reliance on specific geographic regions (e.g., China for certain intermediates) for both APIs can pose geopolitical risks.
  • Raw Material Sourcing: The availability and cost of upstream raw materials for both HCA and PHC synthesis can impact production. Fluctuations in the supply or price of key steroid precursors for HCA or specific chemical building blocks for PHC can create volatility.
  • Environmental Regulations: Increasingly stringent environmental regulations in manufacturing countries can impact production costs and continuity.
  • Intellectual Property (IP): While the primary APIs are off-patent, process patents for improved synthesis or novel polymorphs can influence manufacturing exclusivity and cost.

Key Considerations for Procurement and Sourcing

What due diligence steps are critical for securing a reliable supply of HCA and PHC?

Procurement professionals must implement a multi-faceted approach to identify and qualify suppliers, mitigate risks, and ensure a consistent supply of high-quality APIs.

• Supplier Qualification Process:
  • Regulatory Audit: Conduct thorough on-site audits of manufacturing facilities to verify GMP compliance, quality systems, and operational controls.
  • Technical Review: Evaluate the supplier's manufacturing process, analytical capabilities, and historical batch data for consistency and adherence to specifications.
  • Financial Stability: Assess the financial health of potential suppliers to ensure their long-term viability.
  • Supply Chain Mapping: Understand the supplier's raw material sourcing and identify any single points of failure or reliance on potentially unstable upstream suppliers.
• Risk Mitigation Strategies:
  • Dual Sourcing: Identify and qualify at least two qualified suppliers for each API to reduce reliance on a single source. This is particularly important for PHC given its more concentrated supply base.
  • Contractual Agreements: Establish robust supply agreements that clearly define quality specifications, delivery timelines, pricing mechanisms, change control procedures, and business continuity plans.
  • Inventory Management: Implement appropriate safety stock levels based on lead times, historical consumption, and risk assessment.
  • Market Intelligence: Continuously monitor market trends, pricing, regulatory changes, and potential supply disruptions impacting HCA and PHC.

How can buyers ensure long-term price stability and supply continuity?

Long-term price stability and supply continuity are achieved through strategic supplier relationships, proactive contract negotiation, and a deep understanding of market dynamics.

• Long-Term Contracts: Negotiate multi-year supply agreements that may include price adjustment clauses tied to specific indices or pre-defined market conditions. However, balance long-term commitments with flexibility to adapt to significant market shifts.
• Volume Commitments: Offer clear volume commitments to key suppliers in exchange for preferential pricing and guaranteed allocation during periods of tight supply.
• Joint Forecasting: Collaborate with suppliers on demand forecasting to enable better production planning and resource allocation.
• Technology Transfer Support: For critical APIs like HCA and PHC, consider supporting suppliers in adopting new technologies or improving manufacturing processes that could lead to cost efficiencies or enhanced quality.
• Geographic Diversification: Where feasible, consider diversifying sourcing across different geographic regions to mitigate risks associated with localized disruptions (e.g., natural disasters, trade disputes, or specific country-level regulatory changes).

Key Takeaways

• The supply of Hydrocortisone Acetate is characterized by a broad base of manufacturers primarily located in India and China, offering competitive pricing and high volumes.
• Pramoxine Hydrochloride production is more concentrated among a smaller number of global suppliers, with China and India being key manufacturing hubs.
• Both APIs require strict adherence to pharmacopoeial standards (USP, EP) and Good Manufacturing Practices (GMP).
• Regulatory filings, such as Drug Master Files (DMFs) and Certificates of Suitability (CEPs), are essential for market access in regulated territories.
• Supply chain risks include geopolitical instability, raw material availability, environmental regulations, and concentration of suppliers.
• Robust supplier qualification, dual sourcing strategies, and comprehensive contractual agreements are critical for ensuring reliable supply and price stability.

FAQs

1. What is the typical lead time for obtaining a new batch of Hydrocortisone Acetate from a qualified supplier? The typical lead time for Hydrocortisone Acetate can range from 8 to 16 weeks, depending on the supplier's production schedule, existing inventory, and the volume of the order.
2. Are there any significant intellectual property restrictions that could impact the sourcing of generic Hydrocortisone Acetate or Pramoxine Hydrochloride? The core patents for Hydrocortisone Acetate and Pramoxine Hydrochloride have long expired. Sourcing is generally not restricted by primary API patents, but specific manufacturing processes or novel polymorphic forms may be subject to process patents held by individual manufacturers.
3. What are the primary quality control tests performed on Pramoxine Hydrochloride by API manufacturers? Primary quality control tests for Pramoxine Hydrochloride include assay (purity), identification, related substances (impurities), loss on drying, residue on ignition, and heavy metals, all in accordance with USP and EP monographs.
4. How can a pharmaceutical company verify the GMP compliance of a Pramoxine Hydrochloride supplier in China? Verification of GMP compliance for a Chinese supplier can be achieved through on-site audits conducted by the company's quality assurance team, review of the supplier's regulatory inspection history (e.g., FDA, EMA), and confirmation of relevant GMP certifications.
5. What are the key raw materials or intermediates for Hydrocortisone Acetate production, and are there known supply vulnerabilities for these? Key raw materials for Hydrocortisone Acetate often originate from diosgenin or other steroidal precursors. Supply vulnerabilities can arise from fluctuations in agricultural yields (for natural sources) or the production capacity of specialized chemical intermediates, particularly if these are sourced from a limited number of global suppliers.

Citations

[1] United States Pharmacopeia. (n.d.). Hydrocortisone Acetate. USP-NF. [2] European Directorate for the Quality of Medicines & HealthCare. (n.d.). Certificate of Suitability. EDQM. [3] U.S. Food and Drug Administration. (n.d.). Drug Master Files. FDA.gov. [4] European Pharmacopoeia. (n.d.). Pramoxine Hydrochloride. Ph. Eur. [5] Divi's Laboratories Limited. (2023). Annual Report 2022-23. [6] Laurus Labs Limited. (2023). Annual Report 2022-23. [7] Aarti Industries Limited. (2023). Annual Report 2022-23. [8] Zhejiang NHU Co., Ltd. (2023). Annual Report 2022-23. [9] Zhejiang Medicine Co., Ltd. (2023). Annual Report 2022-23.